Every muscular dystrophy produces the same core symptom: muscle that weakens and wastes progressively, because a structural protein the muscle fiber needs is missing or broken. What separates the types is the pattern — which muscles go first, at what age, and what happens to the heart and lungs along the way. A neurologist looking at a patient is reading that pattern, not the weakness itself.
"Weak muscles" is not a diagnosis. A three-year-old who cannot climb stairs, a 25-year-old who cannot let go of a handshake, and a teenager whose shoulder blades stick out are pointing at three different genes.
Symptoms every muscular dystrophy shares
Across types, the recurring features are:
- Progressive weakness. Unlike an injury, it does not plateau and recover. It advances over years.
- Muscle wasting, sometimes masked by fat and connective tissue replacing muscle, which can make a muscle look bigger while it gets weaker.
- Elevated serum creatine kinase (CK), the enzyme that leaks from damaged muscle fibers. In Duchenne it runs more than ten times the normal ceiling; in Becker, more than five times.
- Heart or breathing involvement in most types, though timing and severity vary enormously.
- A genetic cause, so family history is diagnostic information — but its absence proves nothing, because new mutations happen.
What it is generally not: painful as its main feature, sudden in onset, or accompanied by numbness — numbness and tingling point toward nerve problems rather than muscle. For the coding side, see muscular dystrophy ICD-10 classification.
Duchenne and Becker muscular dystrophy symptoms
These two are the same disease at two severities, both caused by mutations in the DMD gene on the X chromosome, which encodes dystrophin. Together they affect roughly 1 in 3,500 to 5,000 newborn males worldwide, per MedlinePlus Genetics.
Duchenne, earliest signs. Parents most often report general motor delay, gait problems including persistent toe-walking and flat-footedness, or delayed walking. The average age of walking is around 18 months, and diagnosis typically lands at age four or five — often years after the first thing someone noticed.
The Gowers maneuver. A child rising from the floor "walks" his hands up his own thighs to push himself upright, because the hip and thigh muscles cannot do it alone. It is one of the most specific early physical signs in medicine.
Calf pseudohypertrophy. Calves look enlarged and feel firm, but the bulk is fat and fibrous tissue, not contractile muscle. The calf is weaker than it looks. Thighs can show the same thing.
Progression. Weakness starts proximally — hips, thighs, shoulders — and children with Duchenne are typically wheelchair-dependent by around age 12. Cardiomyopathy follows a documented timeline: roughly one third affected by age 14, one half by 18, and essentially all individuals after 18.
Cognitive and behavioral symptoms. Real and frequently missed. The Muscular Dystrophy Association reports that about one third of boys with Duchenne have learning disabilities, with elevated rates of ADHD, autism spectrum disorder, anxiety and mood disorders. Dystrophin is expressed in the brain, not only muscle.
Becker. Same gene, partially functional protein. Onset is later and slower, ambulation is preserved past age 16, and some people remain walking into their sixties. One clinical tell: neck flexor strength is preserved in Becker but not Duchenne. Dilated cardiomyopathy is the most common cause of death, with mean age at death reported in the mid-forties.
Female carriers. Around 76% of carrier females stay asymptomatic. The rest may have muscle weakness, myalgia and cramps, or cardiac findings — left ventricular dilatation in about 19%, with 8% developing overt dilated cardiomyopathy in Duchenne families. Carriers deserve cardiac surveillance, not reassurance by default.
Myotonic dystrophy symptoms look almost nothing like Duchenne
Myotonic dystrophy type 1 (DM1) is the most common adult-onset muscular dystrophy, and it inverts the usual pattern.
Weakness is distal first — hands and feet, causing foot drop and loss of fine manual dexterity — rather than proximal. The defining feature is myotonia: muscle that will not relax on command. The classic complaint is being unable to quickly let go of a grip, and it improves with repeated contractions, the so-called warm-up phenomenon.
Face and neck are heavily involved, producing weak eyelid closure, a weak smile, and a thin face. Nearly everyone develops posterior subcapsular cataracts with a distinctive "Christmas tree" appearance on slit lamp exam, usually becoming symptomatic in the thirties or forties. Cardiac conduction defects — not primarily cardiomyopathy — occur in around 90% and can cause sudden death, which is why pacemakers enter the conversation.
DM1 splits by CTG repeat size into mild (cataracts and mild myotonia, onset 20 to 70), classic (weakness, myotonia, cataracts, arrhythmia, onset 10 to 30), and congenital (severe hypotonia, respiratory insufficiency, intellectual disability, from birth).
FSHD symptoms: face, shoulder blades, feet
Facioscapulohumeral muscular dystrophy is named after the muscles it hits. Scapular winging is the most common initial finding, caused by lower trapezius weakness — the shoulder blade rides up and juts out when the arm moves. Facial weakness shows up as difficulty whistling, an inability to purse the lips, an asymmetric smile, or sleeping with the eyes partly open. Extraocular and bulbar muscles are spared.
Two things make FSHD distinctive. First, asymmetry is common — one side genuinely worse than the other, which patients often assume means an injury. Second, progression is often stuttering: quiet periods interrupted by stretches of rapid decline. Onset is typically in the teens but highly variable, and roughly 20% eventually need a wheelchair. Peroneal weakness causing foot drop can appear without hip girdle weakness, which sometimes sends people down a workup for a pinched nerve first.
Limb-girdle and Emery-Dreifuss patterns
Limb-girdle muscular dystrophy is not one disease but a family of genetically distinct conditions sharing a phenotype: weakness centered on the shoulder and hip girdles, face spared. Onset ranges from childhood to late adulthood, and cardiac and respiratory risk varies by gene, which is why subtype identification matters. See limb-girdle muscular dystrophy.
Emery-Dreifuss muscular dystrophy presents as a triad: joint contractures beginning in early childhood, weakness and wasting in a humeroperoneal distribution (upper arms and lower legs) later spreading to the girdles, and cardiac involvement that can include palpitations, presyncope, syncope, poor exercise tolerance and congestive heart failure. The contractures often precede meaningful weakness, so elbows, Achilles tendons and neck stiffen before anything looks like a muscle disease. More at Emery-Dreifuss muscular dystrophy.
Heart and breathing symptoms are easy to miss
Respiratory weakness rarely announces itself as breathlessness first. According to the MDA, subtle early indicators include morning headaches, mental dullness, difficulty concentrating and nightmares — signs of overnight hypoventilation. A weak cough that cannot clear secretions raises pneumonia risk before anyone notices reduced lung volumes.
Cardiac symptoms are similarly quiet, partly because someone who cannot walk far never loads the heart enough to feel limited. Fatigue, shortness of breath and palpitations are what gets reported, but scheduled echocardiography and rhythm monitoring find the problem earlier than symptoms do.
How symptoms get turned into a diagnosis
The usual sequence is a CK blood test, then genetic testing. A markedly elevated CK in a child with motor delay is a strong pointer, and testing of the DMD gene confirms it — deletion and duplication analysis catches the majority of Duchenne cases, with sequencing for the rest. Muscle biopsy is used less than it once was.
One change worth knowing: on December 16, 2025, the U.S. Department of Health and Human Services added Duchenne muscular dystrophy to the federal Recommended Uniform Screening Panel. This is a recommendation, not a mandate — individual states still have to adopt it, and Ohio, New York and Minnesota moved earlier on their own. The motivation is the diagnostic gap: most children are still identified at four or five, after substantial muscle is already lost.
Where myostatin fits into muscular dystrophy symptoms
Myostatin (GDF-8) is the body's brake on muscle growth. Blocking it makes muscle bigger, which is why it looked like an obvious strategy for diseases defined by muscle loss. The results in muscular dystrophy are a cautionary tale, and they are worth stating plainly.
- MYO-029 (stamulumab), an anti-myostatin antibody, was tested in 116 adults with Becker, FSHD and limb-girdle dystrophy. It was safe apart from cutaneous hypersensitivity at higher doses, and showed a trend toward increased muscle size — but no significant improvement in muscle function.
- ACE-031, a soluble activin receptor decoy, showed trends toward preserved six-minute walk distance, increased lean mass and reduced fat mass in ambulatory boys with Duchenne. The trial was stopped early after the second dosing regimen over epistaxis and telangiectasias — bleeding and small dilated vessels, side effects unrelated to muscle. Background on ACE-031.
- Domagrozumab (PF-06252616), an anti-myostatin antibody, was studied in 121 boys aged 6 to 15 with Duchenne. Muscle volume on MRI increased as the mechanism predicts. The trial missed its primary endpoint on the four-stair-climb test, secondary endpoints did not rescue it, and Pfizer terminated the program.
The pattern across all three: myostatin blockade reliably grows muscle tissue and does not reliably make dystrophic muscle work better. The plausible reason is that in dystrophinopathy the fiber membrane itself is fragile, so adding mass to a fiber that tears under load does not fix the underlying failure. That distinction — bigger versus more functional — remains the open question. See myostatin and Duchenne and anti-myostatin antibodies.
Frequently asked questions
What is usually the very first symptom of muscular dystrophy? It depends on the type. In Duchenne, parents most often report motor delay, toe-walking, flat-footedness or delayed walking. In myotonic dystrophy type 1, it may be difficulty releasing a grip or foot drop. In FSHD, it is often a winging shoulder blade or difficulty whistling.
Can muscular dystrophy symptoms start in adulthood? Yes. Becker onset varies widely, myotonic dystrophy type 1 in its mild form can present between ages 20 and 70, and several limb-girdle subtypes present in adulthood. Late onset does not rule out a genetic muscle disease.
Are enlarged calves a symptom of muscular dystrophy? They can be. In Duchenne, calf pseudohypertrophy means the muscle is enlarged by fat and connective tissue infiltration while being weaker than normal muscle. Large calves alone are not diagnostic — the combination of large, firm calves and functional weakness is what matters.
Does muscular dystrophy cause pain? Pain is not the defining symptom, though cramps, myalgia and contracture-related discomfort occur — some female Duchenne carriers report myalgia and cramps as their main complaint. Progressive weakness is the signal to act on.
Do myostatin inhibitors treat muscular dystrophy symptoms? No approved myostatin inhibitor treats muscular dystrophy. Three separate programs — MYO-029, ACE-031 and domagrozumab — increased muscle size or lean mass without demonstrating functional benefit, and two were stopped for safety or futility. Whether any drug is appropriate for a given person is a prescriber's decision made against a confirmed genetic diagnosis, not something to infer from mechanism.
Educational content, not medical advice. Progressive weakness warrants evaluation by a neuromuscular specialist.